The genomics revolution has unveiled a wealth of poorly characterized proteins. Scientists are often able to produce milligram quantities of proteins for which function is unknown or hypothetical, based only on very distant sequence homology. Broadly applicable tools for functional characterization are essential to the illumination of these orphan proteins. An additional challenge is the direct detection of inhibitors of protein-protein interactions (and allosteric effectors). Both of these research problems are relevant to, among other things, the challenge of finding and validating new protein targets for drug action. Screening collections of small molecules has long been used in the pharmaceutical industry as 1 method of discovering drug leads. Screening in this context typically involves a function-based assay. Given a sufficient quantity of a protein of interest, significant effort may still be required for functional characterization, assay development, and assay configuration for screening. Increasingly, techniques are being reported that facilitate screening for specific ligands for a protein of unknown function. Such techniques also allow for function-independent screening with better characterized proteins. ThermoFluor ® , a screening instrument based on monitoring ligand effects on temperature-dependent protein unfolding, can be applied when protein function is unknown. This technology has proven useful in the decryption of an essential bacterial enzyme and in the discovery of a series of inhibitors of a cancer-related, protein-protein interaction. The authors review some of the tools relevant to these research problems in drug discovery, and describe our experiences with 2 different proteins. (Journal of Biomolecular Screening 2006:854-863) 
T he amount of bioinformation publicly available today is not only vast, comprising well over a million sequences and approximately 200 complete genomes, but also extensive and complex, with information about structure, regulation, interaction partners, and expression more readily accessible than even before. In this sea of information are many proteins of unknown function. Many others have function(s) assigned solely on the basis of sequence similarity. Even for the smaller set of ~30,000 genes in the human genome, there are still many genes that lack a credible annotation. Drugs marketed to date have targeted approximately 500 protein targets, 1 and the remaining 98% of human proteins represents a large source of potential new targets for drug action. Concomitant with the expansion of the search for new drug targets and the increasing cost of drug development, the level of information required to validate a protein as a target for drug discovery has increased.
In parallel, new technologies have deepened our understanding of the complexities of metabolic pathways and signaling cascades. Assignment of function(s) to completely uncharacterized proteins and further annotation of partially characterized proteins are current challenges in biological and biomedical research.
Genomic sequencing has created a demand for methods that can be used to elucidate the function of previously unknown proteins. For enzymes, a biochemical function annotation usually comprises assignment to a class within the Enzyme Commission (EC) scheme. 2 As the concept of protein function has grown to encompass many functions in addition to enzymatic catalysis, annotation has become more complex, and more comprehensive functional schemes, such as the Gene Ontology project, 3 
have arisen.
Experimental evidence is the sine qua non for assignment of protein function. Computational methods can be extremely enlightening, indicating previously unimagined relationships between proteins and often leading to more focused experiments for ongoing characterization studies. The summary of our study of an orphan bacterial protein (below) highlights the impact of sequence-and structure-based analysis on the interpretation of initial experimental results as well as on guiding follow-up experiments in this context. Ultimately, however, most decisions are based largely on experimental results. A key piece of the puzzle is the ability to employ a "universal" screening technique that facilitates a search for ligands independent of any knowledge of the function of the target protein. In some cases, little or nothing may be known about natural ligands or protein function. Experimental data on ligand binding may shed light on protein function and may also indicate possible lead molecules for drug discovery.
We and our colleagues have been involved in the development and application of ThermoFluor ® , 4-8,* a high-throughput screening tool well suited to screening for protein ligands in informationpoor contexts. ThermoFluor ® measures binding affinity by detecting ligand-dependent changes in the thermal stability of a target protein. This technology is readily applied to screening problems where target protein function is unknown or where a functional assay is unavailable. 4 We have also applied ThermoFluor ® to the identification of novel inhibitors of a cancer-related proteinprotein interaction. 8 In principle, ThermoFluor ® also seems likely to succeed in finding ligands that bind to peripheral effector sites, when ligand binding effects on catalytic activity or cognate ligand binding may be subtle. ThermoFluor ® finds broad application in various aspects of the drug discovery process.
Here we review some aspects of the current challenge of decrypting the function of uncharacterized (i.e., orphan) proteins. An overview of some recent reports of experimental approaches to discerning function and/or discovering ligands for orphan proteins is followed by a brief discussion of some challenges inherent to screening for antagonists of proteinprotein interactions. The underlying principles and some details of the use of the new ThermoFluor ® technology, relevant to these 2 screening contexts are then described. Finally, we summarize 2 recent studies from our laboratories involving the application of ThermoFluor ® to ligand discovery. In 1 project, ThermoFluor ® provided initial screening data suggestive of biological function for an orphan bacterial protein.
ThermoFluor ® was also useful in a variety of more complex follow-up experiments that were successful in gaining more detailed information about protein function. In the second study, an initial ThermoFluor ® screen identified 2 related novel classes of specific inhibitors of HDM2:p53, a protein-protein interaction currently being pursued as a target for cancer therapy.
SURVEY OF EXPERIMENTAL METHODS
The survey presented here does not represent a comprehensive overview of experimental methods available. A selection of affinity-based techniques is highlighted, with the primary focus on their applicability to the early drug discovery process.
Relevant reviews that more broadly cover some areas are also cited, where appropriate.
Target-independent assay technologies are based on various biophysical methods that directly monitor the binding between a target protein and a ligand. 9 In this context, the term ligand includes small organic molecules, natural products, and peptides. Traditional techniques such as isothermal calorimetry (ITC), analytical ultracentrifugation (AUC), nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, surface plasmon resonance (SPR), and affinity capillary electrophoresis (ACE) are reliable, precise, information rich, and very efficient in the characterization of molecular interactions. They are widely used as secondary assays for confirmation and profiling of hits obtained from biochemical or cell-based screens. However, the utility of these methods for primary screening is often limited by low throughput and relatively high protein consumption. In addition, many of these techniques require target modification and/or a separation/wash step. These may disturb or disrupt the binding equilibrium of interest and may cause the dissociation of weakly bound compounds.
NMR spectroscopy and X-ray crystallography are extremely useful tools in both the discovery and optimization of drug leads. X-ray crystallography offers detailed structural information on proteins and their complexes in the crystal state. The atomic-level detail provided by 1 or more high-resolution Xray crystal structures can often be used to design subtle ligand modifications that yield profound improvements in binding affinity. NMR provides information about protein flexibility in solution as well as insights into the kinetics of protein-ligand interactions. In addition to the wide variety of more traditional applications of these 2 techniques in drug discovery, [10] [11] [12] [13] both have been applied to fragment-based screening approaches to drug discovery and design. [14] [15] [16] [17] Fragment-based approaches seem particularly well suited to ligand design problems where structural information regarding known ligands is unavailable.
Fesik's group at Abbott Laboratories originally described the application of a fragment-based approach to ligand discovery/ design, referred to as SAR by NMR. 18 A small library of low molecular weight (MW) compounds (MW< 250 Da) is screened by NMR to identify molecules that bind to 2 (or more) distinct yet adjacent binding subsites of the protein. Two relatively low-affinity fragments linked together in an appropriate fashion can yield a larger, more specific, and higher affinity ligand. Because the affinities of the small molecules in the screening collection are expected to be relatively low, in the millimolar range, the compounds are screened at relatively high concentrations. The high compound concentrations required can potentially cause artifacts due to compound solubility problems and pH effects. SAR by NMR appears to be a generally applicable strategy for fragment-based drug discovery and design that combines limited random screening with structure-guided synthetic chemistry. At Abbott Laboratories, the combination of both NMR and X-ray crystallography methods is used *The ThermoFluor for structure-based lead discovery integrated with virtual screening. 16 X-ray crystallography is also useful in fragment-based approaches to drug discovery and design, and reviews of this application have appeared recently. 14, 15, 17, 19 Recent advances in high-throughput crystallography 20 have fueled growth in this area. Earlier computational studies of the molecular fragments most commonly observed in known drugs provide insight into suitable fragments for this new application of X-ray crystallography. 21, 22 Tethering, a novel variant of the fragment-based approach, has been developed by researchers at Sunesis Pharmaceuticals, Inc. 17 This technology was used to explore the flexible proteinprotein interface of the cytokine interleukin-2 (IL-2 [23] [24] [25] ). Based on the X-ray crystal structure of IL-2 with the known antagonist Ro26-4550 bound, 23 the binding pocket of IL-2 was modified by site-directed mutagenesis, creating 10 individual cysteine mutants. A 7000-member library of disulfide-containing fragments was then screened for disulfide formation with each of the 10 mutant proteins. The researchers were able to identify a new and highly adaptive binding site and ultimately were able to achieve a 50-fold improvement in the affinity of an existing low micromolar hit by combining it with the most active class of fragments. This type of "induced-fit" interaction represents a great challenge, for both conventional structural analysis techniques and computational docking methods, due to the difficulties of predicting ligand-dependent protein structure flexibility. SPR (Biacore®) and ACE are medium-throughput methods that can be formatted and automated to run hundreds to thousands of compounds per day. Both methods require covalent modifications: immobilization of the target protein on a sensor chip with SPR and target or ligand labeling with dye for ACE. In a recent report, Shaw and coworkers described the application of ACE to the screening of YihA, an antimicrobial target of unknown biochemical function. 26 In this study, the ACE assay yielded a low primary hit rate of 0.26% and a high rate of hit confirmation (76%). Impressively, approximately 75% of the confirmed hits showed antimicrobial activity against multidrug-resistant pathogenic bacteria. Several assay formats have been developed for the use of ACE in screening for inhibitors of protein-protein interactions. 27 Biacore's SPR technology 28 provides detailed information on the binding affinity and kinetic parameters of a molecular interaction. Applications include target identification and validation, understanding of receptor-ligand and protein-ligand interactions, and determining kinetic parameters for immunoassays and lead optimization. One recent advance with this technology is the integration of SPR with mass spectrometry (MS), enabling both identification and recovery of binding partners. 29 That makes it a valuable technique in the search for biological ligands of orphan receptors, an approach called "ligand fishing."
Similar to the SPR-MS format noted above, mass spectrometrybased techniques have been developed that combine the high selectivity and throughput of MS detection with selection techniques such as size exclusion, affinity chromatography, ultrafiltration, ultracentrifugation, and ACE. [30] [31] [32] Due to the high resolution and sensitivity of mass spectrometry, these assays can be highly multiplexed, identifying active components in large pools of compounds. In addition, the throughput of liquid chromatography/mass spectrometry (LC/MS) can be increased by interfacing multiple high-performance liquid chromatography (HPLC) columns to a single mass spectrometer. However, many affinity-based mass spectrometry methods suffer from the same limitations as traditional separation techniques. For example, some assay formats (e.g., affinity chromatography) require target immobilization. Immobilization of the receptor may have conformational effects, which in turn could affect ligand binding. The stationary phase and linkers can contribute to an increase in false positives due to nonspecific interactions. The development and optimization of the immobilization protocol is often a significant project itself. Ultrafiltration and size exclusion chromatography include a separation/wash step that must be carried out quickly to minimize the loss of lower affinity ligands.
Chu and colleagues 33, 34 demonstrated the use of ACE coupled with online electrospray ionization/mass spectrometry (ESI/MS) detection for the screening of a small tetrapeptide library for ligands to vancomycin. In contrast with other affinity-based mass spectrometry methods, this approach requires neither target modification nor a preliminary purification step. Despite its advantages, the application of this format restricts the binding assay conditions that may be used in screening. Buffers and impurities from the target or compound stock solutions can interfere with mass spectrometric ionization and detection.
Researchers at Novartis AG reported a label-free LC/MS screening technique termed SpeedScreen, formatted in 96-well filtration plates. 35 To streamline the screening process and minimize protein and sample consumption, mixtures with up to 600 compounds per well were used. The target protein and compound pools were incubated in a plate to allow targetligand complex formation, and complexes were then separated from unbound molecules for further analysis. Size exclusion chromatography combined with reversed-phase LC/MS was used to isolate and identify the active compounds.
Recently, a conceptually different mass spectrometry-based method, SUPREX (Stability of Unpurified Proteins from Rates of H/D EXchange), has been carried out in a 96-well plate format. 36 The technique relies on the well-studied phenomenon of ligandinduced thermodynamic stabilization of proteins. The conventional SUPREX assay involves a multipoint titration by urea followed by amide hydrogen/deuterium (H/D) exchange and matrix-assisted laser desorption ionization/mass spectrometry (MALDI/MS) analysis. To increase screening throughput, a single-point SUPREX has been suggested. Test compounds were placed in a 96-well plate and diluted in deuterated buffer containing a fixed concentration of denaturant. The H/D exchange reaction was initiated by the addition of a fully protonated solution of the protein. After a 30-min incubation, the reaction was quenched by trifluoroacetic acid (TFA), and each sample was desalted, concentrated, and analyzed by MALDI/MS. The utility of this assay for primary screening is unclear and needs further validation. One concern is that in the single-point format proposed for screening, the range of binding affinities that can be detected depends on the urea concentration.
The biophysical principle of ligand-induced thermodynamic stabilization of proteins also provides the basis for ThermoFluor ® . Although SUPREX uses chemical denaturation to assess protein stability, ThermoFluor ® measures small changes in protein thermal stability induced by ligand binding. 6 An environmentally sensitive fluorescent dye that interacts specifically with nonnative protein is used as an indicator (Fig. 1) . The midpoint of the protein unfolding transition is defined as the T m (Fig. 2) . Compounds that bind native protein will increase the T m (Fig. 2) , and this temperature shift (∆T m ) is proportional to both ligand concentration and its binding affinity. 7 It is important to emphasize that there is no upper limit on the affinity that can be measured by ThermoFluor ® ; more potent ligands simply give higher T m shifts.
The ThermoFluor ® assay is readily optimized for a target of any biological function and can be configured in a high-throughput 384-well format (Fig. 2) , making it applicable to both primary screening and hit profiling. It has also proven useful in the selection of protein constructs for use in screening and X-ray crystallography. Because ThermoFluor ® is a simple, direct, affinitybased assay, it usually requires only 1 additional reagent-the fluorescent dye-and does not involve any target modification or separation steps. In most screens, low false-positive rates are observed. In addition, the assay generates data comparable across numerous projects, compound libraries, and target families, thus providing a valuable tool for chemical genomics.
ThermoFluor ® can provide additional information regarding the mechanism of compound activity, distinguishing covalent from equilibrium binding ligands and protein stabilizers from protein destabilizers. For example, Shoichet and colleagues recently described a set of high-throughput screening (HTS)identified compounds with activity toward several unrelated targets. [37] [38] [39] [40] It has been proposed that the (nonspecific) activity of these compounds was associated with aggregation. Based on our results, many of these compounds destabilize protein tertiary structure and do not test positively in ThermoFluor ® or other biophysical assays. 39 Thus, such "problem" compounds may be avoided in a ThermoFluor ® screen.
Concentration-response curves obtained with ThermoFluor ® allow rank ordering of hits according to binding affinity and also provide information about binding stoichiometry. The mechanism of action can be further explored by varying the assay conditions to probe specific binding sites of the target protein or evaluate hits in competition with known ligands. As described below, our functional decryption of an orphan bacterial protein involved a variety of different ThermoFluor ® assay configurations that together allowed for characterization of enzyme-cofactor-substrate(s) interactions.
APPLICATIONS OF THERMOFLUOR ® ®
Protein-protein interactions represent a rich source of potential targets for drug action. However, nonenzymatic protein targets that evolved to form relatively large protein-protein interfaces with their cognate binding partner(s) currently present a challenge for pharmaceutical discovery. From a drug design perspective, the cognate ligand for a small-molecule binding site often provides relatively obvious useful information for ligand design, whereas the extraction of similar insight from a protein-protein complex is less straightforward. To put it simply, a small-molecule enzyme substrate (e.g., sugar, nucleotide) is more drug-like than a protein. The design and discovery of small-molecule inhibitors of protein-protein interactions is a burgeoning field, and review of this area is well beyond the scope of this article. Several recent reviews should provide the interested reader with an introduction to the field. [41] [42] [43] [44] [45] [46] [47] [48] The search for target-specific inhibitors of protein-protein interactions is an emerging area of drug discovery that presents unique challenges. For these protein targets, there may not be an obvious function-dependent signal that is useful for direct monitoring of small-molecule binding. Typical genomic-level experiments for determination of protein-protein interactions, such as 2-hybrid screens, are difficult to perform on the scale necessary for screening large compound collections. In other systems (e.g., enzymes), assays can often be configured to directly monitor enzyme activity toward a substrate or substrate analog. Compound collections are screened for molecules that affect the enzyme activity being monitored. In these cases, detection establishes the desired function. Details of the mechanism of action and mode of ligand binding require more painstaking follow-up experiments.
The complexity of the screening process is increased if protein function is unknown or if no direct activity readout is accessible. Screening for ligands for these challenging systems can be addressed by the use of screening protocols that are independent of protein function. In these cases, care must be taken to avoid complications due to interactions between molecules being screened and assay reagents. On the other hand, molecules that bind to the target protein may not elicit the desired biochemical response, and further characterization of all screening hits is required to establish the desired effect on function (e.g., inhibition of enzyme activity or protein-protein binding).
Drug discovery for protein-protein interaction systems and orphan proteins is similar with respect to the challenge presented by the initial method of screening. Multiple assays may be required to determine that a small molecule has the desired biochemical activity.
In the preceding section, we described technologies relevant to the search for ligands for proteins that currently represent particular screening challenges. We have also briefly outlined the biophysical underpinnings of ThermoFluor ® and provided some details of its use in various screening contexts. After introducing orphan proteins and protein-protein interactions as 2 challenging target classes for drug discovery, we now summarize a representative study in each of these 2 areas that highlights the application of ThermoFluor ® . Much of our screening expertise has been gained in conjunction with the development and application of ThermoFluor ® , and it is therefore our tool of choice for challenging screens such as those described below. Other screening technologies, such as those surveyed above, could undoubtedly be applied to similar problems. Our summaries of case studies should provide the reader with some general guidance with respect to approaching these types of screening problems and should also indicate the usefulness of ThermoFluor ® as a screening tool in these contexts.
APPLICATION OF THERMOFLUOR ® ® TO FUNCTION DECRYPTION WITH AN UNKNOWN BACTERIAL PROTEIN
In this antibacterial drug discovery project, target proteins were selected according to several criteria, using a relatively high-throughput microbial concordance approach as described previously. 49 To focus on targets that might lead to broadspectrum antibiotics, sequence analysis was carried out to establish the existence of homologous proteins in at least 2 of the following species: Bacillus subtilis, Enterococcus faecalis, Escherichia coli, and Staphylococcus epidermis. Gene essentiality was measured in knockout studies with Streptococcus pneumoniae, and only those proteins shown to be essential to bacterial survival were of interest. Finally, sequence comparison with yeast was used to focus on targets less likely to lead to cross-reactivity problems with eukaryotic host proteins. The proteins that passed these criteria possessed several desirable properties for a potential target of antibiotic action.
As part of this antibacterial drug discovery effort, we studied an essential bacterial protein of unknown function, CFE97, from S. pneumoniae. 4 In parallel with large-scale screening of our proprietary drug discovery collection to find potential drug leads, we screened our functional probe library in an attempt to decrypt the function of the unknown protein CFE97. The functional probe library is an evolving collection of biochemically informative small molecules, including known enzyme substrates and inhibitors, sugars, and nucleotides. This collection has been assembled as a tool to aid in the functional decryption of orphan proteins. In many validation studies, ThermoFluor ® has detected the binding of known small-molecule ligands to their cognate target proteins. On this basis, we are developing a ThermoFluor ® -based approach to function decryption of orphan proteins, and our study of CFE97 highlights the power and usefulness of the approach.
Initial testing of our functional probe library revealed the enzyme cofactor pyridoxal phosphate (PLP) to be the most active screening hit, causing an extremely large thermal shift of 25 °C in the T m of CFE97 at a PLP concentration of 75 µM (Fig. 2) . 4 For perspective, 55 of the ca. 3000 compounds screened reproducibly shifted the T m by more than 1 °C and only 2 by more than 10 °C. Interestingly, the pyridoxamine form of the cofactor (pyridoxamine 5´-phosphate [PMP]) was a lesser but still significant screening hit (5 °C). These 2 results together provided the initial indication that PLP might act as a cofactor for CFE97 and prompted in-depth analysis of sequence relationships.
Basic local alignment search tool (BLAST) searching 50 against the nonredundant sequence database (NR database dated April 13, 2001 ) was encouraging but also confusing. Many matches were found with sequence identities between 30% and 40%. 4 Unfortunately, most of these matches had only putative functions, tentatively assigned on the basis of sequence homology. Recent studies related to this issue have established that 60% global sequence identity is required to assign all 4 EC numbers with 90% accuracy. 51, 52 The reliability of the conclusions we could draw from the observed relationships was unclear to us. However, most of the putative enzymes were assigned roles as transaminases or decarboxylases and would thus use PLP as a cofactor. Searching against this large sequence database was consistent with a cofactor role for PLP with CFE97, but did not give a clear functional assignment and thus did not indicate a clear forward path for our characterization effort. The tentative nature of the function assignment for the most significant sequence matches clouded the meaning of this result.
BLAST searching 50 against the Protein Data Bank (PDB) 53 sequences proved more telling. 4 At the time of our initial analysis (PDBAA database dated April 13, 2001), only 1 sequence in this relatively small collection showed a significant relationship to CFE97. 3-Amino-5-hydroxybenzoic acid (AHBA) synthase from Amycolatopsis mediterranei was found to be 25% identical and 44% similar to CFE97 (Fig. 3) . One of the AHBA synthase structures was a complex with PLP bound (PDB ID 1B9H 54 ), and closer analysis of this structure and its relation to CFE97 proved crucial to our characterization effort. Fifty-six percent sequence identity was found for the 25 residues closest to the bound PLP molecule. For 10 key PLP-contacting residues, the identity is 70%, and the changes in the 3 variant residues are conservative. All direct binding contacts could be conserved in CFE97. A similarly compelling relationship was observed for a more recent PDB entry, ArnB aminotransferase from Salmonella typhimurium (PDB ID 1MDX 55 ), later in the course of our study (Fig. 3) . The virtually complete conservation of the PLP cofactor binding interactions between CFE97 and these 2 structurally characterized enzymes convinced us of the significance of our initial screening result.
Because ThermoFluor ® relies on monitoring the thermal denaturation of a protein, a thorough biophysical characterization is a crucial part of the optimization process undertaken prior to running a ThermoFluor ® screen. In the case of CFE97, the information gained from this characterization was useful in the decryption of function as well as in establishing optimal conditions for ThermoFluor ® screening. Initial biophysical studies with CFE97 suggested that the protein might exist as a dimer in solution, and this was confirmed by a battery of biophysical measurements. 4 As we explored the known characteristics of aminotransferases and other PLP-using enzymes, subsequent to our initial screening and structure-based studies, we noted that many functioned as homodimers. 4, 56 This was consistent with the biochemical relevance of PLP binding by CFE97.
An extensive set of follow-up experiments provided further support for a cofactor role for PLP with CFE97 and also indicated possible biochemical roles for this enzyme. 4 ThermoFluor ® screening of CFE97 with PLP bound (CFE97:PLP) established that selected amino acids could convert CFE97:PLP to CFE97:PMP and that glutamate (Glu) was the preferred amino acid substrate in this reaction. To explore these results further, UV-visible spectroscopy demonstrated that addition of PLP to CFE97 led to the observation of a characteristic Schiff base absorbance spectrum. Addition of Glu to CFE97:PLP yielded absorbance changes consistent with conversion to the PMP form of the complex. The initial ThermoFluor ® results hinted at a potential preference for nucleotide sugars, and this was confirmed with follow-up experiments based on an expanded set of relevant reagents. Searching in BRENDA [57] [58] [59] [60] number of results. However, combining this criterion with an additional ligand, glutamate, yielded a much smaller list of hits comprised mainly of transaminases and glutamate dehydrogenases. Previous studies by ourselves and others have established that ligands are strong predictors of protein function. [61] [62] [63] Taken together, our experimental and computational results allowed us to make a fairly narrow assignment of function with some confidence.
This study was an excellent learning experience with a powerful new tool for the study of protein-ligand binding. 4 Relatively straightforward reconfigurations of the initial screening assay were used to test our hypothesis about Glu-dependent conversion of PLP to PMP and to discriminate between different amino acid substrates. A further layer of complexity allowed us to use ThermoFluor ® to probe potential amine acceptors. Other experimental technologies were applied to further explore and confirm the conclusions drawn from the results of our initial ThermoFluor ® studies and sequence-and structure-based analyses. Public information and tools, ranging from relatively old biochemistry textbooks to the most up-to-date versions of BLAST 50 and the National Center for Biotechnology Information (NCBI) sequence databases, provided crucial data to our decryption effort. For this protein, basic biophysical characterization of the protein as a dimer provided a helpful piece of information. Relatively laborintensive "manual" analysis of sequence relationships in conjunction with visual analysis of protein structure, motivated by our initial identification of PLP as a ligand, provided almost conclusive (in this case) evidence of close functional relationships.
APPLICATION OF THERMOFLUOR ® ® TO THE DISCOVERY OF BENZODIAZEPINEDIONE INHIBITORS OF THE HDM2:P53 PROTEIN-PROTEIN INTERACTION
Inhibition of the HDM2:p53 protein-protein interaction is an emerging target for cancer drug discovery. 64, 65 Human homolog of mouse double minute protein MDM2 (HDM2) effects regulation of p53 activity by modulation of p53 transcriptional effects as well as by targeting p53 for degradation via the proteasome. 66 The HDM2:p53 interface comprises an HDM2 binding site composed of several sequentially discrete structural elements from the N-terminal domain of this protein and 2 turns of a single α-helix from p53. 67 Thus, although the minimal imaginable truncated peptide that might adopt the bound conformation and present side chains appropriately for binding is still large (MW ca. 1 kDa) in comparison to most known drugs, it is small relative to the full protein ligand. Does this type of "sidedness," where 1 contributor to the protein-protein interface is a relatively small structural element of the protein, indicate a protein-protein target that may be more amenable to small-molecule drug discovery? It may yet be too early to answer this question generally, but this feature does seem attractive. Another attractive feature of HDM2:p53, from the perspective of drug design, is the welldefined, deep binding pocket on the surface of HDM2 (Fig. 4) . 67 To date, we have tested more than 300,000 compounds from our corporate screening collection for binding to the N-terminal domain of HDM2 using our proprietary ThermoFluor ® screening technology. As detailed above, ThermoFluor ® allows a highthroughput search for ligands that shift the thermal denaturation curve of the target protein. Interestingly, perhaps, HDM2 has a relatively low hit rate in ThermoFluor ® screening, when compared to many other protein targets that we have screened (unpublished results). Primary ThermoFluor ® screening hits are evaluated for binding to the p53 binding site in a competitive displacement assay, based on a fluorescent derivative of a p53-derived helical peptide. 8, 68 This screening protocol consistently identified hits in 2 chemical series, one of which, a series of certain benzodiazepinediones, proved amenable to optimization. 7, 66 In this project, medicinal chemistry-based optimization was tracked with the peptide displacement assay rather than the ThermoFluor ® assay.
Crystallographic efforts were ultimately successful with this target, yielding structures for complexes of several analogs in this series (Fig. 4) . 8 These results established that the identified analogs competed for binding to the p53 binding site, consistent with our peptide displacement assay results. A particularly interesting aspect of the structure of the complex shown in Figure 4 is that the small molecule effectively mimics the most important binding contacts of the p53 helix. 8 The substituted phenyl rings of the bound molecule mimic the key i, i + 4, and i + 7 side chains of the p53-derived peptides, filling the deep pocket occupied by the Leu, Trp, and Phe helix side chains in the p53 peptide complexes (this aspect of the structure is discussed in greater detail elsewhere 69 ). It is encouraging to find that ThermoFluor ® , a relatively new HTS technology, can achieve success with a protein-protein target, a class perceived to be particularly challenging for drug discovery. Although we do not have data to suggest that ThermoFluor ® provides a general screening solution for protein-protein interactions, our results with HDM2 further validate this technology as a drug discovery screening tool. It is also important to note that application of ThermoFluor ® to multidomain protein(-protein) systems is expected to be limited. The relatively complex melting curves characteristic of multidomain proteins (or systems) currently preclude application of ThermoFluor ® to screening of these systems. A group at Roche has also recently reported the discovery of reasonably drug-like small-molecule inhibitors of HDM2-p53 that show therapeutic promise. 70 Taken together with our results for this target, these results may be indicating that HDM2-p53 is a protein-protein target that is particularly amenable to smallmolecule drug discovery, or that our ability to succeed with protein-protein targets in general is significant.
SUMMARY
The determination of the function of orphan proteins and the discovery of specific inhibitors of protein-protein interactions represent 2 current challenges in biochemical research. Proteinprotein interactions are central to biochemical pathways, and increased understanding of these biomolecular interactions will also deepen our understanding of normal and abnormal biochemical processes. Decrypting newly identified proteins should improve our understanding of many new and known biochemical mechanisms and pathways. One of many anticipated outcomes from both of these areas of research is the identification and characterization of new protein targets for drug action. Progress in both of these areas of research may have important implications for the discovery and development of new drugs.
Here we have discussed aspects of these 2 research challenges and briefly reviewed experimental and computational methods relevant to these problems. An overview of the underlying biophysical principle and details of the use of ThermoFluor ® was presented. This was followed by summaries of findings from 2 projects. We have described efforts to use HTS data, commonly collected in the pharmaceutical industry to find drug leads, as a tool to help functional assignment of the previously unannotated bacterial protein CFE97. In particular, we have used the additional knowledge from screening data to refine and reinforce signals from other sources, including sequence and structure. We have also described successful efforts to find small-molecule inhibitors of the HDM2:p53 protein-protein interaction. One aim of the present review has been to highlight the usefulness and general applicability of ThermoFluor ® to the problem of ligand discovery and protein characterization in various contexts. Given the underlying fundamental biophysical principle on which it is based and the wide applicability of the technology, as evidenced by the projects summarized here 4, 8 as well as other published [5] [6] [7] 41 and unpublished results, we expect the use and variety of applications of ThermoFluor ® to continue to grow in the foreseeable future.
